POMDOCTOR LIMITED Announces Closing of Initial Public Offering

Rhea-AI Summary

POMDOCTOR (Nasdaq: POM) closed its initial public offering on Oct 9, 2025, selling 5,000,004 ADSs at $4.00 per ADS (six ADSs equal one Class A ordinary share). The ADSs began trading on the Nasdaq Global Market on Oct 8, 2025 under ticker POM. The company received aggregate gross proceeds of approximately $20.0 million before underwriting discounts and expenses. The underwriter, Joseph Stone Capital, was granted a 45-day option to buy up to an additional 750,000 ADSs at the public offering price less underwriting discounts. The offering was conducted on a firm commitment basis.

Positive

• Gross proceeds of approximately $20.0 million
• 5,000,004 ADSs sold at $4.00 per ADS
• ADSs began trading on Nasdaq Global Market on Oct 8, 2025
• Underwriter option for up to 750,000 ADSs exercisable 45 days

Negative

• Proceeds reported before underwriting discounts and other expenses
• Underwriter's 750,000 ADS option creates potential near‑term dilution

Insights

Capital Markets Strategist

POMDOCTOR closed a Nasdaq IPO, raising about $20.0 million; watch the underwriter option and net proceeds.

POMDOCTOR LIMITED completed an offering of 5,000,004 ADSs at $4.00 per ADS, generating aggregate gross proceeds of approximately $20.0 million. The ADSs began trading on Nasdaq on October 8, 2025, and the offering formally closed on October 9, 2025. The company granted the underwriter a 45‑day option to buy up to 750,000 additional ADSs at the offering price less discounts.

The business impact hinges on the actual net proceeds after underwriting discounts and expenses, and on whether the underwriter exercises the option within the 45‑day window. The SEC declared the registration effective on September 30, 2025, confirming regulatory clearance for the offering. Key near‑term items to watch include the exercise of the overallotment option within the next 45 days and disclosures of gross versus net proceeds in the final prospectus.

GUANGZHOU, China, Oct. 9, 2025 /PRNewswire/ -- POMDOCTOR LIMITED (Nasdaq: POM) (the "Company" or "POMDOCTOR"), a leading online medical services platform for chronic diseases in China, today announced the closing of its initial public offering (the "Offering") of 5,000,004 American Depositary Shares ("ADSs") at a public offering price of US$4.00 per ADS. Six ADSs represent one Class A ordinary share, par value US$0.0001 per share, of the Company. The ADSs began trading on Nasdaq Global Market on October 8, 2025 under the ticker symbol "POM."

The Company received aggregate gross proceeds of approximately US$20.0 million from the Offering, before deducting underwriting discounts and other related expenses. In addition, the Company has granted the underwriters an option to purchase up to an additional 750,000 ADSs, exercisable within 45 days from the date of the final prospectus at the public offering price, less underwriting discounts.

The Offering was conducted on a firm commitment basis. Joseph Stone Capital, LLC acted as the underwriter for the Offering (the "Underwriter").

A registration statement on Form F-1 relating to the Offering has been filed with the U.S. Securities and Exchange Commission (the "SEC") (File Number: 333-285771), as amended, and was declared effective by the SEC on September 30, 2025. The Offering was made only by means of a prospectus, forming a part of the effective registration statement. Copies of the final prospectus relating to the Offering, when available, may be obtained from Joseph Stone Capital, LLC by email at corporatefinance@josephstonecapital.com, by standard mail at 585 Stewart Avenue, Unit L60-C, Garden City, NY 11530, or by telephone at +1 888-302-5548. In addition, copies of the final prospectus relating to the Offering, when available, may be obtained via the SEC's website at www.sec.gov.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company's securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

About POMDOCTOR LIMITED

POMDOCTOR LIMITED is a leading online medical services platform for chronic diseases in China, ranking sixth on China's Internet hospital market based on the number of contracted doctors in 2022, according to Frost & Sullivan. Focusing on chronic disease management and pharmaceutical services, the Company offers a one-stop platform for medical services, organically connecting patients with doctors and pharmaceutical products. The Company's operations primarily include internet hospital and pharmaceutical supply chain, connecting users, pharmacies, suppliers, medical professionals, and other healthcare participants. Through this model, POMDOCTOR aims to enhance the efficiency and transparency of the healthcare value chain. The Company's mission is to provide effective prevention and treatment solutions to alleviate patients' sufferings from illnesses. Its vision is to become the most trustworthy medical and healthcare services platform. For more information, please visit the Company's website: http://ir.7shiliu.com.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "will," "would," "should," "could," "may" or other similar expressions in this prospectus. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and other filings with the SEC.

For more information, please contact:

POMDOCTOR LIMITED
Investor Relations Department
Email: ir@7lk.com

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com

View original content:https://www.prnewswire.com/news-releases/pomdoctor-limited-announces-closing-of-initial-public-offering-302580105.html

SOURCE POMDOCTOR LIMITED

FAQ

When did POMDOCTOR (POM) begin trading on Nasdaq?

ADSs began trading on the Nasdaq Global Market on Oct 8, 2025 under ticker POM.

How many ADSs did POMDOCTOR sell in its IPO and at what price?

The company sold 5,000,004 ADSs at a public offering price of $4.00 per ADS.

How much gross capital did POMDOCTOR raise in the offering?

Aggregate gross proceeds were approximately $20.0 million, before underwriting discounts and expenses.

What is the ADS to ordinary share ratio for POMDOCTOR?

Six ADSs represent one Class A ordinary share of the company.

Does the IPO include an overallotment option for additional shares?

Yes, the underwriter has an option to purchase up to 750,000 ADSs, exercisable within 45 days of the final prospectus date.

Who acted as underwriter for POMDOCTOR's IPO?

Joseph Stone Capital acted as the underwriter for the offering.